Can analysts adopt a bullish outlook for Cardiome Pharma Corp. (NASDAQ:CRME)?

January 11, 2018 - By Clifton Ray

 Can analysts adopt a bullish outlook for Cardiome Pharma Corp. (NASDAQ:CRME)?
Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.26, from 0.83 in 2017Q2. It is positive, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported.
Wells Fargo Mn has 800 shares for 0% of their portfolio. Renaissance Limited Liability Co invested in 411,413 shares. Westfield Cap Mngmt L P holds 0.08% or 4.86M shares. Gp One Trading Lp accumulated 0% or 917 shares. Clough Prtn Limited Partnership owns 2.88 million shares for 0.41% of their portfolio. Bancshares Of Montreal Can invested 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). 3.09 million are held by Putnam Investments Llc. Comml Bank Of Nova Scotia Tru Comm reported 10 shares. Geode Ltd Liability Co invested in 0% or 18,731 shares. Ardsley Advisory has 0.01% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 36,200 shares. Citadel Limited Liability invested in 16,339 shares. Art Advsr holds 16,718 shares. Toronto Dominion Natl Bank has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Valley Advisers stated it has 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Ontario – Canada-based Scotia Capital Inc has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME).

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. On Wednesday, November 15 the stock rating was maintained by Canaccord Genuity with “Buy”. The company was upgraded on Friday, December 15 by Mackie. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, August 22 report. The company was downgraded on Wednesday, October 12 by Mackie. Zacks downgraded Cardiome Pharma Corp. (NASDAQ:CRME) on Tuesday, August 11 to “Buy” rating. The company was initiated on Wednesday, June 1 by H.C. Wainwright. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by Canaccord Genuity on Monday, July 17. Brean Capital maintained Cardiome Pharma Corp. (NASDAQ:CRME) on Friday, March 11 with “Buy” rating. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by H.C. Wainwright on Wednesday, November 22. The stock has “Speculative Buy” rating by Mackie on Friday, May 6. Below is a list of Cardiome Pharma Corp. (NASDAQ:CRME) latest ratings and price target changes.

15/12/2017 Broker: Mackie Rating: Buy Upgrade
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
15/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $8 New Target: $5 Maintain
22/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
21/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $8.0 Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5000
17/07/2017 Broker: Canaccord Genuity Rating: Buy New Target: $8 Reinitiate

The stock decreased 0.24% or $0.004 during the last trading session, reaching $1.576. About 53,815 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since January 11, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $54.37 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

More news for Cardiome Pharma Corp. (NASDAQ:CRME) were recently published by: Seekingalpha.com, which released: “Cardiome Pharma: The Pieces Are Coming Together” on May 25, 2017. Prnewswire.com‘s article titled: “Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit” and published on January 10, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.